Drug Interactions and Side Effects of Co-Administration of Chloroquine/Hydroxychloroquine and Azithromycin: on the Issue of Rational Pharmacotherapy of Patients with COVID-19 with Antimalarial Drugs
This review analyzes existing approaches to the treatment of COVID-19 patients with antimalarial drugs from the standpoint of rational pharmacotherapy. Particular attention is paid to drug interactions and side effects of co-administration of chloroquine/hydroxychloroquine and azithromycin, considering the problem of cardiotoxicity and the high likelihood of cardiovascular disease in middle-aged and elderly people with COVID-19. The article discusses the prospects of using another representative from the group of antimalarial drugs - mefloquine in the treatment of COVID-19. Special attention is paid to the “proarrhythmogenic” side effects of azithromycin therapy, as well as to the problem of resistance of microorganisms to macrolides during antibiotic therapy of pneumonia, in particular to azithromycin. In conclusion, the article discusses the possibilities of alternative methods in the treatment of this disease..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Рациональная фармакотерапия в кардиологии - 16(2020), 3, Seite 481-486 |
| Sprache: |
Englisch ; Russisch |
|---|
| Beteiligte Personen: |
O. V. Gaisenok [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Azithromycin |
|---|
| doi: |
10.20996/1819-6446-2020-06-08 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ040735141 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ040735141 | ||
| 003 | DE-627 | ||
| 005 | 20240413191125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20996/1819-6446-2020-06-08 |2 doi | |
| 035 | |a (DE-627)DOAJ040735141 | ||
| 035 | |a (DE-599)DOAJc2527fb533f745d7ab71da95a7c80a10 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a O. V. Gaisenok |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Interactions and Side Effects of Co-Administration of Chloroquine/Hydroxychloroquine and Azithromycin: on the Issue of Rational Pharmacotherapy of Patients with COVID-19 with Antimalarial Drugs |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This review analyzes existing approaches to the treatment of COVID-19 patients with antimalarial drugs from the standpoint of rational pharmacotherapy. Particular attention is paid to drug interactions and side effects of co-administration of chloroquine/hydroxychloroquine and azithromycin, considering the problem of cardiotoxicity and the high likelihood of cardiovascular disease in middle-aged and elderly people with COVID-19. The article discusses the prospects of using another representative from the group of antimalarial drugs - mefloquine in the treatment of COVID-19. Special attention is paid to the “proarrhythmogenic” side effects of azithromycin therapy, as well as to the problem of resistance of microorganisms to macrolides during antibiotic therapy of pneumonia, in particular to azithromycin. In conclusion, the article discusses the possibilities of alternative methods in the treatment of this disease. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a chloroquine | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a azithromycin | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a side effects | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 773 | 0 | 8 | |i In |t Рациональная фармакотерапия в кардиологии |d Столичная издательская компания, 2012 |g 16(2020), 3, Seite 481-486 |w (DE-627)DOAJ000071544 |x 22253653 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2020 |g number:3 |g pages:481-486 |
| 856 | 4 | 0 | |u https://doi.org/10.20996/1819-6446-2020-06-08 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/c2527fb533f745d7ab71da95a7c80a10 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.rpcardio.online/jour/article/view/2230 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1819-6446 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2225-3653 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2020 |e 3 |h 481-486 | ||